Healthcare provider profile · identity verified

Carlos E Perez Semidei, M.D.

General Practice · TOA ALTA, PR · NPI 1750350864

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Omeprazole	Omeprazole	517	134
Famotidine	Famotidine	485	136
Simvastatin	Simvastatin	438	175
Synthroid	Levothyroxine Sodium	390	125
Pantoprazole Sodium	Pantoprazole Sodium	228	56
Lisinopril	Lisinopril	221	86
Losartan Potassium	Losartan Potassium	214	73
Amlodipine Besylate	Amlodipine Besylate	212	78
Ezetimibe	Ezetimibe	201	80
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	179	96
Gabapentin	Gabapentin	173	66
Methylprednisolone	Methylprednisolone	160	108
Metoprolol Succinate	Metoprolol Succinate	160	57
Metformin Hcl	Metformin Hcl	156	58
Montelukast Sodium	Montelukast Sodium	154	66
Diclofenac Potassium	Diclofenac Potassium	153	89
Diclofenac Sodium Er	Diclofenac Sodium	118	68
Atorvastatin Calcium	Atorvastatin Calcium	115	44
Baclofen	Baclofen	111	55
Cefuroxime	Cefuroxime Axetil	111	88
Hydrochlorothiazide	Hydrochlorothiazide	110	47
Rosuvastatin Calcium	Rosuvastatin Calcium	109	54
Tamsulosin Hcl	Tamsulosin Hcl	107	39
Azithromycin	Azithromycin	106	82
Dexamethasone	Dexamethasone	104	73
Clopidogrel	Clopidogrel Bisulfate	93	42
Albuterol Sulfate Hfa	Albuterol Sulfate	82	28
Meclizine Hcl	Meclizine Hcl	78	31
Candesartan Cilexetil	Candesartan Cilexetil	77	30
Fluticasone Propionate	Fluticasone Propionate	76	36
Naproxen	Naproxen	72	36
Alendronate Sodium	Alendronate Sodium	69	31
Pregabalin	Pregabalin	64	14
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	61	20
Irbesartan	Irbesartan	61	23
Quetiapine Fumarate	Quetiapine Fumarate	60	24
Trijardy Xr	Empaglifloz/Linaglip/Metformin	60	16
Nifedipine Er	Nifedipine	59	25
Allopurinol	Allopurinol	56	23
Doxazosin Mesylate	Doxazosin Mesylate	54	22
Fluconazole	Fluconazole	53	39
Glipizide	Glipizide	53	23
Prednisone	Prednisone	52	18
Finasteride	Finasteride	49	23
Lantus	Insulin Glargine,hum.Rec.Anlog	48	14
Nabumetone	Nabumetone	48	28
Esomeprazole Magnesium	Esomeprazole Magnesium	47	13
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	47	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	46	18
Carvedilol	Carvedilol	45	14
Eliquis	Apixaban	44	suppressed
Colchicine	Colchicine	43	14
Diclofenac Sodium	Diclofenac Sodium	43	22
Amitriptyline Hcl	Amitriptyline Hcl	41	26
Clindamycin Hcl	Clindamycin Hcl	41	35
Glipizide Er	Glipizide	41	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	28
Lansoprazole	Lansoprazole	39	suppressed
Methotrexate	Methotrexate Sodium	39	12
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	36	13
Acyclovir	Acyclovir	35	16
Levofloxacin	Levofloxacin	35	32
Clarithromycin	Clarithromycin	32	28
Jentadueto	Linagliptin/Metformin Hcl	32	suppressed
Moxifloxacin Hcl	Moxifloxacin Hcl	31	26
Sure Comfort	Syring-Needl,disp,insul,0.3 Ml	31	suppressed
Sertraline Hcl	Sertraline Hcl	30	14
Sucralfate	Sucralfate	29	12
Temazepam	Temazepam	29	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	27	24
Furosemide	Furosemide	27	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	24
Meloxicam	Meloxicam	26	16
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	26	17
Glimepiride	Glimepiride	25	suppressed
Latanoprost	Latanoprost	25	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	25	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	13
Lactulose	Lactulose	24	14
Terconazole	Terconazole	24	15
Verapamil Er	Verapamil Hcl	24	suppressed
Pentoxifylline	Pentoxifylline	22	suppressed
Buspirone Hcl	Buspirone Hcl	20	12
Clonazepam	Clonazepam	20	12
Dicyclomine Hcl	Dicyclomine Hcl	20	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	20	12
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	20	17
Prednisolone Acetate	Prednisolone Acetate	20	13
Jardiance	Empagliflozin	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	17	suppressed
Sildenafil Citrate	Sildenafil Citrate	17	suppressed
Methylprednisolone Acetate	Methylprednisolone Acetate	16	13
Ondansetron Hcl	Ondansetron Hcl	16	13
Sure Comfort	Syringe And Needle,insulin,1ml	16	suppressed
Ibuprofen	Ibuprofen	15	11
Ketoconazole	Ketoconazole	15	suppressed
Metronidazole	Metronidazole	15	15
Trazodone Hcl	Trazodone Hcl	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Chlorzoxazone	Chlorzoxazone	14	12
Clonidine Hcl	Clonidine Hcl	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Prednisolone Sodium Phosphate	Prednisolone Sodium Phosphate	14	11
Trandolapril	Trandolapril	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	12
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	11
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error